IL-1<i>β</i>and IL-6 Are Highly Expressed in RF+IgE+ Systemic Lupus Erythematous Subtype

Wu, Yongkang; Cai, Bei; Zhang, Junlong; Shen, Bin; Huang, Zhuochun; Tan, Chunyu; Baan, Carla C.; Wang, Lanlan

doi:10.1155/2017/5096741

Cited by 24 publications

(21 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We evaluated these 33 publications in detail. We found that 23 publications fulfilled the eligibility criteria (3006 patients; Figure 1) [13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]. While all studies investigated SLE patients, only 6 of them focused on LN [13,19,22,25,27,31].…”

Section: Resultsmentioning

confidence: 99%

“…While all studies investigated SLE patients, only 6 of them focused on LN [13,19,22,25,27,31]. Fifteen studies had available data for additional meta-analysis (1921 patients) [14,15,16,17,18,19,21,24,25,26,27,28,31,32,35]. The detailed characteristics of the selected studies are shown in Table 1.…”

Section: Resultsmentioning

confidence: 99%

“…The majority of the studies were conducted in Asia (11 studies), while others were from Europe, northern America, and Africa (eight, two, and two studies, respectively). There were 15 cross-sectional studies [14,17,19,21,22,23,24,26,27,29,31,32,33,34,35] and eight prospective cohort studies [13,15,16,18,20,25,28,30]. All studies were conducted in adults except for one study which was done in children with juvenile-onset SLE [19].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis

Puapatanakul

Chansritrakul

Susantitaphong

et al. 2019

IJMS

View full text Add to dashboard Cite

There is increasing evidence of a correlation between interferon-inducible protein 10 (IP-10) and disease activity of systemic lupus erythematosus (SLE) and lupus nephritis (LN). We conducted a comprehensive search on IP-10 using MEDLINE, Scopus, and Cochrane electronic databases from the beginning to the end of December 2017. All studies that compared serum and/or urine IP-10 between active SLE/LN patients and any control groups were identified and included in this systematic review and meta-analysis. The mean difference (MD) of IP-10 level among active SLE and LN patients, as well as the correlation of IP-10 with disease activity, were meta-analyzed using a random-effects model. From 23 eligible studies, 15 provided adequate data for meta-analysis. Serum IP-10 was significantly elevated in patients with active SLE compared to non-active SLE patients (MD 356.5 pg/mL, 95% CI 59.6 to 653.4, p = 0.019). On the other hand, the levels of serum IP-10 was not different between active LN and non-active LN. However, serum IP-10 was positively correlated with disease activity like SLE disease activity index (SLEDAI) (pooled r = 0.29, 95% CI 0.22 to 0.35, p < 0.001). Furthermore, urine IP-10 tended to be higher in patients with active LN compared to non-active LN patients but this did not reach statistical significance (MD 3.47 pg/mgCr × 100, 95% CI −0.18 to 7.12, p = 0.06). Nevertheless, urine IP-10 was positively correlated with renal SLEDAI (pooled r = 0.29, 95% CI 0.05 to 0.50, p = 0.019). In conclusion, serum and urine IP-10 levels may be useful in monitoring the disease activity of SLE and LN. Serum IP-10 was correlated with systemic disease whereas urine IP-10 was a useful biomarker for detecting active LN.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis

Puapatanakul

Chansritrakul

Susantitaphong

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Previous studies had reported significant increase in serum hepcidin in SLE patients, when compared with control subjects [16]. Other numerous studies had stated that IL-6 in SLE patients was significantly higher than in control subjects [17][18][19][20][21].…”

Section: Discussionmentioning

confidence: 99%

Serum hepcidin and interleukin-6 in systemic lupus erythematosus patients: crucial factors for correction of anemia

El-Shafey

Kamel

Fikry

et al. 2020

Egypt Rheumatol Rehabil

View full text Add to dashboard Cite

Background: The incidence rate of anemia of chronic disease (ACD) in systemic lupus erythematosus (SLE) ranges between 30 and 80%. Serum iron is the main regulator of hepatic hepcidin production. Interleukin-6 (IL-6) upregulates hepcidin expression. The aim of this study is to compare between serum hepcidin and IL-6 in SLE patients and control subjects, and to find out if they are correlated with each other and with disease activity in order to find their role in treatment of anemia in SLE patients. The study was carried out on 50 SLE patients, suffering from anemia, diagnosed according to SLICC revision of the ACR classification criteria for SLE, and 50 healthy individuals, taken as control. Disease activity was assessed using the SLE disease activity index (SLEDAI-2 K). Serum hepcidin and IL-6 were measured by ELISA kit. Results: There was a highly statistically significant difference in serum hepcidin and IL-6 levels between patients and control subjects. There was a statistically significant correlation between serum hepcidin and IL-6 in SLE patients. Moreover, both of them were correlated with SLEDAI and ESR and negatively correlated with hemoglobin. The mean value of serum hepcidin in SLE patients with normocytic normochromic anemia was higher than that in patients with microcytic hypochromic anemia. However, this difference did not reach a statistically significant level. Conclusion: High serum IL-6 and hepcidin levels are associated with anemia in SLE. They are correlated with each other and with disease activity. Although our study revealed serum hepcidin to be correlated with disease activity, it should not be used as a marker of disease activity in SLE patients as our patient's group was SLE patients suffering from ACD. However, IL-6 inhibition should be considered in patients with SLE with anemia to guide the control of anemia of chronic diseases resulting from cytokine production as a result of high disease activity in SLE patients. It should be noted that the occurrence of ACD associated with IL-6 flare up could be a player in other systemic rheumatic diseases and is not specific to SLE patients.

show abstract

“…Increased levels have been seen in SLE patients and they appear to be influenced by anti-dsDNA (Additional file 4 : Table S2). High levels of IL-6 have also been found in SLE [ 44 , 45 ]. Both IL-6 and IL-8 have been shown to be up-regulated by endothelial cells treated with IgG APLA in vitro [ 46 ].…”

Section: Discussionmentioning

confidence: 99%

Cytokine and autoantibody clusters interaction in systemic lupus erythematosus

et al. 2017

View full text Add to dashboard Cite

BackgroundEvidence supports the existence of different subphenotypes in systemic lupus erythematosus (SLE) and the pivotal role of cytokines and autoantibodies, which interact in a highly complex network. Thus, understanding how these complex nonlinear processes are connected and observed in real-life settings is a major challenge. Cluster approaches may assist in the identification of these subphenotypes, which represent such a phenomenon, and may contribute to the development of personalized medicine. Therefore, the relationship between autoantibody and cytokine clusters in SLE was analyzed.MethodsThis was an exploratory study in which 67 consecutive women with established SLE were assessed. Clinical characteristics including disease activity, a 14-autoantibody profile, and a panel of 15 serum cytokines were measured simultaneously. Mixed-cluster methodology and bivariate analyses were used to define autoantibody and cytokine clusters and to identify associations between them and related variables.ResultsFirst, three clusters of autoantibodies were defined: (1) neutral, (2) antiphospholipid antibodies (APLA)-dominant, and (3) anti-dsDNA/ENA-dominant. Second, eight cytokines showed levels above the threshold thus making possible to find 4 clusters: (1) neutral, (2) chemotactic, (3) G-CSF dominant, and (4) IFNα/Pro-inflammatory. Furthermore, the disease activity was associated with cytokine clusters, which, in turn, were associated with autoantibody clusters. Finally, when all biomarkers were included, three clusters were found: (1) neutral, (2) chemotactic/APLA, and (3) IFN/dsDNA, which were also associated with disease activity.ConclusionThese results support the existence of three SLE cytokine-autoantibody driven subphenotypes. They encourage the practice of personalized medicine, and support proof-of-concept studies.Electronic supplementary materialThe online version of this article (10.1186/s12967-017-1345-y) contains supplementary material, which is available to authorized users.

show abstract

IL-1βand IL-6 Are Highly Expressed in RF+IgE+ Systemic Lupus Erythematous Subtype

Cited by 24 publications

References 47 publications

Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis

Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis

Serum hepcidin and interleukin-6 in systemic lupus erythematosus patients: crucial factors for correction of anemia

Cytokine and autoantibody clusters interaction in systemic lupus erythematosus

Contact Info

Product

Resources

About